After a brutal fight for Allergan, from which most shareholders benefited financially, the primary combatants end dueling lawsuits
Setup a free account to get access to this article (no credit card required).
View Full ArticleMark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.
Get articles and insights from our weekly newsletter.
By entering your email, you agree to our Terms of Service and Privacy Policy.
